The objective of the present case-control study was to determine prevalence factors associated with the detection of equine herpesvirus type 1 (EHV-1) by quantitative PCR (qPCR) in horses presented to veterinarians with clinical signs related to an upper respiratory tract infection and/or acute onset of neurological disease from March 2008 to December 2014. Nasal secretions and whole blood from 4228 equids with acute onset of fever, respiratory signs and/or neurological deficits were tested by qPCR for EHV-1. Categorical analyses were performed to determine the association between observations and EHV-1. A total of 117/4228 (2.7 per cent) equids tested qPCR-positive for EHV-1, with most of the isolates belonging to the non-neuropathogenic genotype (N 752 ). EHV-1 PCR-positive equids were over-represented in racing horses. Depression, anorexia, nasal discharge and coughing were significantly less frequently reported in the EHV-1 qPCR-positive equids compared with the EHV-1 qPCR-negative cases. Neurological deficits were more frequently reported in the EHV-1 qPCR-positive cases. This study provides contemporary information on the frequency of EHV-1 detection by qPCR in blood and nasal secretions from horses with fever, respiratory signs and neurological deficits.
Equine herpesvirus type 1 (EHV-1) is an important equine viral pathogen that can induce respiratory disease and less frequently abortions in pregnant mares, early neonatal death in foals and myeloencephalopathy (Ostlund 1993) . Outbreaks of EHV-1 can cause devastating losses and severely impact the equine industry, as exemplified by recent outbreaks at riding schools, racetracks, horse shows and veterinary hospitals throughout North America and Europe (Henninger and others 2007 , Burgess and others 2012 , Traub-Dargatz and others 2013 . Infection of the respiratory tract with EHV-1 is generally mild in older or previously infected horses, while the disease observed in young immunologically naive horses is often severe, lasts for two to three weeks, and is characterised by a biphasic fever, depression, anorexia, coughing, and nasal and ocular discharge that is initially serous and then becomes mucopurulent (Ostlund 1993 , Van Maanen 2002 . Lower respiratory tract disease associated with secondary bacterial infection, tachypnoea, anorexia and depression can be observed in young foals. The objective of the present study was to gain a better understanding of the prevalence and epidemiology of EHV-1 shed by horses presented to veterinarians with an upper respiratory tract infection and/or acute onset of neurological signs from March 2008 to December 2014.
Materials and methods Study population
Two hundred and thirty-nine equine veterinary practices located in 38 states of the USA were enrolled in a voluntary surveillance programme for equine respiratory pathogens. The participating veterinarians were asked to collect blood and nasal secretions from equine patients with signs of acute upper respiratory tract infection and/or neurological deficits. The case definition of horses to be sampled included one or more of the following signs: unexplained fever (T>101.5°F), depression, nasal discharge, coughing and acute neurological signs (ataxia, weakness, urinary incontinence, recumbency). Acute onset of neurological disease was included in the case definition in order to sample horses with possible EHV-1 myeloencephalopathy. Case submission occurred over 82 months (March 2008 to December 2014 . A diagnosis of EHV-1 infection was made based on the presence of clinical signs and the laboratory detection of EHV-1 via quantitative PCR (qPCR) as previously described (Pusterla and others 2009).
Data collection
A questionnaire was used to collect information pertaining to the cases and their clinical signs. The questionnaire included signalment (age, breed, gender), use (racing, show, pleasure, breeding, others) , vaccination history and presence of clinical signs at the time of sample collection (general attitude, appetite, rectal temperature, nasal discharge, ocular discharge, presence of cough, distal limb oedema, ataxia, weakness, incontinence, recumbency).
Sample collection and analysis
Sample collection was performed by the attending veterinarians. Wearing disposable gloves, the attending veterinarians collected 5 ml of whole blood in an evacuated EDTA vacutainer tube (Monoject, Tyco Healthcare Group LP, Massachusetts, USA) by direct venipuncture. This was followed by the collection of nasal secretions using two 6 00 rayon-tipped swabs (Puritan Products Company LLC, Guilford, Maine, USA) as previously described (Pusterla and others 2011) . Samples were kept refrigerated and shipped on ice overnight to the laboratory.
Nucleic acid extractions from whole blood and nasal secretions were performed on the day of sample arrival to the laboratory using an automated nucleic acid extraction system (CAS-1820 X-tractor Gene, Corbett Life Science, Australia) according to the manufacturer's recommendations. Blood and nasal secretions were assayed for the presence of the glycoprotein B (gB) gene and the DNA polymerase (ORF 30) gene of EHV-1 (Pusterla and others 2009). To determine sample quality and efficiency of nucleic acid extraction, all samples were assessed for the presence of the housekeeping gene eGAPDH as previously described (Pusterla and others 2009) . Absolute quantitation of EHV-1 target molecules was performed using standard curves for the gB gene of EHV-1 and eGAPDH and expressed as EHV-1 gene copies per million cells.
Statistical analysis
Associations between horses either qPCR-positive or qPCR-negative for EHV-1 and categorical variables were evaluated using Fisher's exact test (two categories), exact χ 2 tests (three or more nominal categories) and the exact Kruskal-Wallis test (ordinal categories). For all statistical analyses, values of P≤0.05 were considered significant.
Results
A total of 117/4228 (2.7 per cent) cases tested qPCR-positive for both the gB and ORF 30 gene of EHV-1. There were 47 and 100 equids, which tested EHV-1 qPCR-positive in blood and nasal secretions, respectively. Thirty-three equids tested qPCR-positive for EHV-1 in both blood and nasal secretions. Non-neurotropic EHV-1 genotype (N 752 ) was more frequently detected in blood and nasal secretions compared with neurotropic genotype (D 752 ; Table 1 ). There were no significant differences in viral loads between N 752 and D 752 in both blood and nasal secretions ( Table 1) .
The ages of the EHV-1 qPCR-positive horses ranged from 3 months to 33 years (median 7.2 years; Table 2 ). The breeds of EHV-1 qPCR-positive horses included Quarter Horse (41), thoroughbred (23), warmblood (13), pony breed (9), Arabian (5), American Paint Horse (3), standardbred (3), draft horse breed (2), other breeds (7) and no reported breed (9). Further, there were 2 EHV-1 qPCR-positive mules. Among the 117 EHV-1 qPCR-positive cases, there were 47 mares/fillies, 15 stallions/ colts, 45 geldings and 10 animals with no reported gender. The actual or intended use for the EHV-1 qPCR-positive animals was pleasure riding (40), show (39), racing (19), breeding (1), others (2) and not reported (16). Fever, depression, anorexia and nasal discharge were the most commonly reported clinical signs among EHV-1 qPCR-positive animals. Vaccine status was unknown for 78 EHV-1 qPCR-positive horses. Thirty-three horses had been vaccinated against EHV-1 while six horses had never been vaccinated. Eighteen EHV-1 qPCR-positive horses had reported acute onset of neurological signs including ataxia (18), urinary incontinence (6), weakness (2) and recumbency (2).
The age of the EHV-1 qPCR-negative equids ranged from 2 weeks to 36 years (median 6.8 years; Table 2 ). Cases belonged to the following breeds: Quarter Horse (1346), thoroughbred (566), warmblood (407), Arabian (294), American Paint Horse (250), pony breed (181), standardbred (86), draft horse breed (55), Spanish breed (11), other breeds (547) and no reported breed (356). Further, there were 12 EHV-1 qPCR-negative mules or donkeys. Among the 4111 EHV-1 qPCR-negative cases, there were 1505 mares/fillies, 599 stallions/colts, 1721 geldings and 286 animals with no reported gender. The actual or intended use for the EHV-1 qPCR-negative equids was pleasure riding (1400), show (1204), racing (424), breeding (199), others (356) and not reported (528). Fever (2375), depression (2404), anorexia (1936), nasal discharge (2948) and coughing (1959) were the most commonly reported clinical signs among EHV-1 qPCR-negative animals. Vaccine status was unknown for 2178 EHV-1 qPCR-negative horses. In total, 1508 horses had been vaccinated against EHV-1 while 425 horses had never been vaccinated. And 175 EHV-1 qPCR-negative horses had reported acute onset of neurological signs including ataxia (148), urinary incontinence (17), weakness (14) and recumbency (16).
Significant associations were found between EHV-1 qPCR-positive horses and the qPCR-negative cases for use and specific clinical signs. A significant higher prevalence of EHV-1 qPCR-positive animals was found in racing horses (P=0.005) compared with qPCR-negative racing horses. Depression (P=0.004), anorexia (P=0.013), nasal discharge (P=0.0001) and coughing (P=0.0001) were significantly less frequently reported in the EHV-1 qPCR-positive horses compared with the EHV-1 qPCR-negative cases. Neurological deficits (P=0.0001) were significantly more frequently reported in EHV-1 qPCR-positive horses compared with the EHV-1 qPCR-negative cases. There were no significant differences between EHV-1 qPCR-positive and EHV-1 qPCR-negative equids for the remaining prevalence factors (P>0.05).
Discussion
EHV-1 is associated with upper respiratory tract infection and generally affects horses less than three years of age with the majority of affected horses being less than one year of age. The initial clinical signs include acute fever, depression, anorexia, mandibular lymphadenopathy and profuse serous nasal discharge. In adult horses, the disease is generally mild or subclinical unless major complications arise such as abortion in pregnant mares or myeloencephalopathy. The study results show a low detection rate of 2.7 per cent for EHV-1 among 4228 cases presented for acute onset of fever, respiratory signs and/or neurological deficits. Overall only 33 horses tested EHV-1 positive by qPCR in both blood and nasal secretions. The low agreement between the two biological samples reflects the temporal variations in viral kinetics of EHV-1 and highlights the importance to always test both biological samples in a suspect EHV-1 (Allen and Breathnach 2006) . The discrepancy between the studies may relate to the specific EHV-1 genotype used in the experimental study as well as the small number of study horses.
Although study cases represented a wide range of ages, 65 per cent of them were ≤10 years of age, which reflects the higher susceptibility of young animals to infectious respiratory pathogens (Mumford and others 2003) . While every age group appeared to be susceptible to EHV-1, the greater frequency of detection of EHV-1 in younger horses may relate to the clinical expression of the disease as adult horses display generally mild or subclinical disease unless major complications arise such as abortion in pregnant mares or myeloencephalopathy. Although a variety of breeds and uses were represented among the study horses, it was interesting to notice, however, that racing horses were over-represented among qPCR-positive EHV-1 animals compared with the control study population. This observation may relate to the fact that latent EHV-1 infection appears to be detected at a higher frequency in thoroughbreds (Allen and others 2008 , Pusterla and others 2010 . Further, management factors, preventative protocols and stress levels (i.e. exercise) specific to each use may have accounted for the observed differences. Despite a large number of submissions with unknown vaccination history, a similar percentage of control study horses and EHV-1 qPCR-positive horses were vaccinated against EHV-1/-4. Currently available vaccines against EHV-1/-4 do not reliably block infection and viral shedding, the development of viremia (EHV-1 only) or the establishment of latency (Ma and others 2013) . However, the significant reduction in viral shedding observed in vaccinated horses provides reasonable justification for booster vaccination of non-exposed horses at risk for infection in order to reduce viral shedding in the event of infection to EHV-1. By enhancing herd immunity, it is hoped that the level of infectious virus circulating in the at-risk population is decreased and, in turn, that the risk of individual horses in the population developing disease will be reduced.
Fever (65.0 per cent) was the most commonly reported clinical sign reported with EHV-1 qPCR-positive equids. Additional signs reported in equids that tested qPCR-positive for EHV-1 included nasal discharge (48.7 per cent), depression (43.6 per cent), anorexia (36.7 per cent), coughing (26.5 per cent), ocular discharge (19.6 per cent), neurological deficits (15.4 per cent) and limb oedema (7.7 per cent). The clinical signs reported in the EHV-1 PCR-positive equids were in agreement with previous reports (Ostlund 1993 , Van Maanen 2002 . Among EHV-1 qPCR-negative cases, nasal discharge (71.7 per cent), depression (58.5 per cent), fever (57.8 per cent), coughing (47.7 per cent) and anorexia (47.1 per cent) were the most commonly reported clinical signs. The difference in frequency of reported clinical signs between the two study groups likely related to the differences in aetiological agents associated with the respiratory disease (Pusterla and other 2011) . Neurological signs included ataxia, weakness, urinary incontinence or recumbency *Denotes statistically significant differences between groups EHV-1, equine herpesvirus type 1
In conclusion, this study provides valuable and contemporary information on the frequency of EHV-1 detected by qPCR in blood and nasal secretions from horses with acute onset of fever, respiratory signs and/or neurological signs. The results point to the fact that racing horses were over-represented among the EHV-1 PCR-positive cases.
